Subscribe or Manage Preferences
Joseph M. Connors, MD, gives examples of how personalized medicine has influenced how he treats patients with lymphoid malignancies and how his patients have positively responded to these treatments. [ Read More ]
The BMT CTN 0901 is a randomized phase 3 trial that compared outcomes by conditioning intensity, reduced-intensity conditioning (RIC) versus myeloablative conditioning (MAC) in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML); the results of this trial were [ Read More ]
Midostaurin, a multitargeted small-molecule FMS-like tyrosine kinase 3 receptor (FLT3) inhibitor, has demonstrated single-agent activity in patients with acute myeloid leukemia (AML) harboring activating both internal tandem duplication (ITD) and tyrosine kinase domain (TKD) FLT3 mutations.1 The randomized phase 3 [ Read More ]
In contrast to current recommendations to continue tyrosine kinase inhibitor therapy indefinitely, emerging evidence indicates that patients with sustained molecular responses (MRs) on imatinib therapy may achieve deep MRs and durable treatment-free remission (TFR) with nilotinib in patients with chronic-phase [ Read More ]
The pivotal ENESTnd study demonstrated that frontline nilotinib (300 mg and 400 mg twice daily [BID]) treatment resulted in higher rates of deep molecular response and lower rates of disease progression compared with imatinib in newly diagnosed patients with chronic [ Read More ]
The prognosis of adult patients with relapsed and/or refractory acute lymphoblastic leukemia (ALL) who have had prior allogeneic hematopoietic stem-cell transplantation (allo-HSCT) is poor, underscoring the need for novel therapeutic options. Blinatumomab is a bispecific T-cell engaging (BiTE®) CD19-directed antibody [ Read More ]
Joseph M. Connors, MD, ruminates on the staggering increase in the cost of cancer treatments and how oncologists can help ensure their patients are receiving the most valuable care. [ Read More ]
The tyrosine kinase inhibitors imatinib and dasatinib are used extensively as first-line therapy in patients with chronic myeloid leukemia (CML); however, there has been no direct comparison of quality of life (QoL) with these 2 agents in this setting. The [ Read More ]
Targeted immunotherapy with T-cells expressing a CD19-targeting 19-28z chimeric antigen receptor (CAR) has demonstrated high antileukemia activity in adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL). Park and colleagues reported the long-term safety and antitumor activity of 19-28z [ Read More ]
Persistence of minimal residual disease (MRD) after first-line induction therapy is associated with a higher risk of relapse compared with achievement of complete MRD response in patients with acute lymphoblastic leukemia (ALL), underscoring the need for interventional strategies that can [ Read More ]